{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:37:35Z","timestamp":1792219055619,"version":"4.4.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ctrv.2026.103121","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:37:41Z","timestamp":1774543061000},"page":"103121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Hematological immune-related adverse events associated with checkpoint inhibitors"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4592-4620","authenticated-orcid":false,"given":"M\u00e9lanie","family":"Janson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Cherifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hippolyte","family":"Bardet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gandhi","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2026.103121_b0005","doi-asserted-by":"crossref","first-page":"S755","DOI":"10.1016\/j.annonc.2023.09.2347","article-title":"1313MO Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB\u2013IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy","volume":"34","author":"Besse","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103121_b0010","doi-asserted-by":"crossref","unstructured":"Tawbi HA, Hodi FS, Lipson EJ, et al. Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047. J Clin Oncol Off J Am Soc Clin Oncol. Published online December 13, 2024:JCO2401124. doi:10.1200\/JCO.24.01124.","DOI":"10.1200\/JCO.24.01124"},{"key":"10.1016\/j.ctrv.2026.103121_b0015","article-title":"Autoimmune complications of immunotherapy: pathophysiology and management","volume":"369","author":"Chan","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2026.103121_b0020","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103121_b0025","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-Related adverse events of PD-1 and PD-L1 Inhibitors in Clinical Trials: a Systematic Review and Meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"issue":"20","key":"10.1016\/j.ctrv.2026.103121_b0030","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.3390\/cancers14205030","article-title":"Immune Checkpoint Inhibitor-Related Cytopenias: about 68 cases from the French Pharmacovigilance Database","volume":"14","author":"Martin","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103121_b0035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/ejh.13187","article-title":"Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review","volume":"102","author":"Tanios","year":"2019","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103121_b0040","first-page":"13","article-title":"Management and Outcomes of Hematological Immune-related adverse events: Systematic Review and Meta-analysis","volume":"45","author":"Wilson","year":"2022","journal-title":"J Immunother Hagerstown Md 1997"},{"key":"10.1016\/j.ctrv.2026.103121_b0045","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 - An\u00e9mies H\u00e9molytiques Auto-Immunes de l\u2019adulte. Accessed July 15, 2025. https:\/\/www.has-sante.fr\/jcms\/p_3536031\/fr\/anemies-hemolytiques-auto-immunes-de-l-adulte."},{"issue":"20","key":"10.1016\/j.ctrv.2026.103121_b0050","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1182\/blood-2010-03-276162","article-title":"IgA-mediated human autoimmune hemolytic anemia as a result of hemagglutination in the spleen, but independent of complement activation and Fc\u03b1RI","volume":"116","author":"Chadebech","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103121_b0055","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","article-title":"Hematologic Complications of Immune Checkpoint Inhibitors","volume":"24","author":"Davis","year":"2019","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103121_b0060","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103121_b0065","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001622","article-title":"Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade \u22652 immune-related adverse events in patients with cancer","volume":"8","author":"Allouchery","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103121_b0070","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/bjh.14654","article-title":"Guidelines on the management of drug\u2010induced immune and secondary autoimmune, haemolytic anaemia","volume":"177","author":"Hill","year":"2017","journal-title":"Br J Haematol"},{"issue":"54","key":"10.1016\/j.ctrv.2026.103121_b0075","first-page":"139","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"2016","author":"Michot","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.ctrv.2026.103121_b0080","unstructured":"Kroll MH, Rojas-Hernandez C, Yee C. Hematologic complications of immune checkpoint inhibitors."},{"issue":"1","key":"10.1016\/j.ctrv.2026.103121_b0085","doi-asserted-by":"crossref","DOI":"10.1186\/s12979-020-00208-7","article-title":"Autoimmune hemolytic anemia: current knowledge and perspectives","volume":"17","author":"Michalak","year":"2020","journal-title":"Immun Ageing"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103121_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-021-04690-x","article-title":"Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review","volume":"101","author":"Ghanem","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2026.103121_b0095","doi-asserted-by":"crossref","unstructured":"Brodsky RA. Warm Autoimmune Hemolytic Anemia. Solomon CG, ed. N Engl J Med. 2019; 381(7): 647-654. doi:10.1056\/NEJMcp1900554.","DOI":"10.1056\/NEJMcp1900554"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103121_b0100","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/asheducation-2018.1.382","article-title":"Autoimmune hemolytic anemia","volume":"2018","author":"Hill","year":"2018","journal-title":"Hematology"},{"key":"10.1016\/j.ctrv.2026.103121_b0105","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?","volume":"122","author":"Michot","year":"2019","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103121_b0110","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/ajh.27339","article-title":"Drug\u2010induced autoimmune hemolytic anemias related to immune checkpoint inhibitors, therapeutic management, and outcome","volume":"99","author":"Pla\u00e7ais","year":"2024","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103121_b0115","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/ajh.25448","article-title":"Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors","volume":"94","author":"Leaf","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103121_b0120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajh.24570","article-title":"A randomized and double\u2010blind controlled trial evaluating the safety and efficacy of rituximab for warm auto\u2010immune hemolytic anemia in adults (the RAIHA study)","volume":"92","author":"Michel","year":"2017","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103121_b0125","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/bjh.12541","article-title":"A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia","volume":"163","author":"Birgens","year":"2013","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103121_b0130","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1182\/blood-2016-11-693689","article-title":"How I treat autoimmune hemolytic anemia","volume":"129","author":"Go","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103121_b0135","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.autrev.2014.11.014","article-title":"Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies","volume":"14","author":"Reynaud","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"16","key":"10.1016\/j.ctrv.2026.103121_b0140","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood-2011-06-363556","article-title":"Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies","volume":"119","author":"Barcellini","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103121_b0145","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ajh.23909","article-title":"Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia\u2010associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC\/MW and GOELAMS)","volume":"90","author":"Quinquenel","year":"2015","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103121_b0150","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3324\/haematol.2020.250522","article-title":"Efficacy of recombinant erythropoietin in autoimmune haemolytic anaemia: a multicentre international study","volume":"106","author":"Fattizzo","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103121_b0155","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1182\/bloodadvances.2023011798","article-title":"Recombinant erythropoietin in autoimmune hemolytic anemia with inadequate bone marrow response: a prospective analysis","volume":"8","author":"Fattizzo","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103121_b0160","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/bjh.17387","article-title":"Immune thrombocytopenia after immune checkpoint inhibitor therapy","volume":"193","author":"Amanam","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2026.103121_b0165","article-title":"Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count","author":"Khellaf","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2026.103121_b0170","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 - Purpura thrombop\u00e9nique immunologique de l\u2019adulte. Accessed July 15, 2025. https:\/\/www.has-sante.fr\/jcms\/p_3578446\/fr\/purpura-thrombopenique-immunologique-de-l-adulte."},{"issue":"6","key":"10.1016\/j.ctrv.2026.103121_b0175","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3324\/haematol.2021.279484","article-title":"Treatment of drug-induced immune thrombocytopenias","volume":"107","author":"Marini","year":"2022","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2026.103121_b0180","first-page":"1187","article-title":"Sirolimus combined Dexamethasone As the First-Line Therapy for newly Diagnosed Adult Primary Immune Thrombocytopenia: a Multicenter, Open-Label, prospective","volume":"144","author":"Feng","year":"2024","journal-title":"Randomized Controlled Clinical Trial Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103121_b0185","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune Checkpoint Inhibitor Rechallenge after Immune-Related adverse events in patients with Cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103121_b0190","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3324\/haematol.2017.175810","article-title":"Rational management approach to pure red cell aplasia","volume":"103","author":"Balasubramanian","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2026.103121_b0195","unstructured":"Padhi P, White TM, Cetin N. Successful Treatment of Nivolumab plus Ipilimumab\u2013Mediated Pure Red-Cell Aplasia and Diabetes with Cyclosporine. 2021;11(5)."},{"issue":"2","key":"10.1016\/j.ctrv.2026.103121_b0200","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12185-018-2446-y","article-title":"Response to cyclosporine a and corticosteroids in adult patients with acquired pure red cell aplasia: serial experience at a single center","volume":"108","author":"Wu","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ctrv.2026.103121_b0205","unstructured":"Aplasies m\u00e9dullaires acquises et constitutionnelles. Haute Autorit\u00e9 de Sant\u00e9. Accessed October 12, 2025. https:\/\/www.has-sante.fr\/jcms\/p_3431519\/fr\/aplasies-medullaires-acquises-et-constitutionnelles."},{"issue":"1","key":"10.1016\/j.ctrv.2026.103121_b0210","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12885-020-06763-y","article-title":"Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect","volume":"20","author":"Boegeholz","year":"2020","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103121_b0215","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"147","key":"10.1016\/j.ctrv.2026.103121_b0220","first-page":"170","article-title":"Hematological immune related adverse events after treatment with immune checkpoint inhibitors","volume":"2021","author":"Kramer","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.ctrv.2026.103121_b0225","first-page":"15","article-title":"Association of thrombocytopenia with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis based on the data from FDA adverse event reporting system database","author":"Liu","year":"2024","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103121_b0230","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1634\/theoncologist.2017-0531","article-title":"Delayed autoimmune toxicity occurring several months after cessation of Anti\u2010PD\u20101 therapy","volume":"23","author":"Parakh","year":"2018","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103121_b0235","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103121_b0240","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103121_b0245","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety Profile of Nivolumab Monotherapy: a Pooled Analysis of patients with Advanced Melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103121_b0250","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103121_b0255","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in patients Treated with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103121_b0260","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1634\/theoncologist.2017-0133","article-title":"Immune-Related adverse events as a Biomarker in Non-Melanoma patients Treated with Programmed Cell Death 1 Inhibitors","volume":"22","author":"Judd","year":"2017","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103121_b0265","first-page":"1","article-title":"Immune-related adverse events and Survival in Solid Tumors Treated with Immune Checkpoint Inhibitors: a Systematic Review and Meta-Analysis","volume":"43","author":"Petrelli","year":"2020","journal-title":"J Immunother Hagerstown Md 1997"},{"issue":"Supplement_1","key":"10.1016\/j.ctrv.2026.103121_b0270","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1182\/blood-2019-132203","article-title":"Hematologic Immune-Related adverse events from Immune Checkpoint Inhibitors: a Systematic Review of Case-Reports and Case-Series","volume":"134","author":"Gnanapandithan","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103121_b0275","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00262-021-03068-2","article-title":"Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival","volume":"71","author":"Haddad","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103121_b0280","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103121_b0285","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events: a retrospective study from VigiBase update in 2024 looking for emergent safety signals","volume":"14","author":"L\u2019Orphelin","year":"2024","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103121_b0290","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann Oncol"},{"issue":"34","key":"10.1016\/j.ctrv.2026.103121_b0295","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with Nivolumab and Ipilimumab because of adverse events: a Pooled Analysis of Randomized phase II and III Trials","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103121_b0300","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4819-2","article-title":"Efficacy of anti-PD-1\/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)","volume":"18","author":"Tachihara","year":"2018","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103121_b0305","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2326-6066.CIR-17-0220","article-title":"Durable Clinical Benefit in Metastatic Renal Cell Carcinoma patients who Discontinue PD-1\/PD-L1 Therapy for Immune-Related adverse events","volume":"6","author":"Martini","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103121_b0310","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103121_b0315","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103121_b0320","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","article-title":"Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related adverse events in patients with NSCLC","volume":"6","author":"Santini","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103121_b0325","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000604","article-title":"Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy","volume":"8","author":"Haanen","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"30","key":"10.1016\/j.ctrv.2026.103121_b0330","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.19.00320","article-title":"Resumption of Immune Checkpoint Inhibitor Therapy after Immune-Mediated Colitis","volume":"37","author":"Abu-Sbeih","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103121_b0335","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0711-0","article-title":"Concurrent therapy with immune checkpoint inhibitors and TNF\u03b1 blockade in patients with gastrointestinal immune-related adverse events","volume":"7","author":"Badran","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103121_b0340","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0756-0","article-title":"Budesonide treatment for microscopic colitis from immune checkpoint inhibitors","volume":"7","author":"Hughes","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T23:19:51Z","timestamp":1779232791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":68,"alternative-id":["S0305737226000356"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103121","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hematological immune-related adverse events associated with checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103121"}}